Carvedilol and Red cell distribution width increased - a phase IV clinical study of FDA data

Summary:

Red cell distribution width increased is reported as a side effect among people who take Carvedilol (carvedilol), especially for people who are male, 60+ old, also take Aspirin, and have Hereditary neuropathic amyloidosis.

The phase IV clinical study analyzes which people have Red cell distribution width increased when taking Carvedilol. It is created by eHealthMe based on reports of 110,224 people who have side effects when taking Carvedilol from the FDA, and is updated regularly.

What is Carvedilol?

Carvedilol has active ingredients of carvedilol. It is often used in high blood pressure. eHealthMe is studying from 112,649 Carvedilol users. Check the latest studies of Carvedilol.

What is Red cell distribution width increased?

Red cell distribution width increased is found to be associated with 604 drugs and 656 conditions by eHealthMe. Check the latest studies of Red cell distribution width increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 24, 2026

110,224 people reported to have side effects when taking Carvedilol.
Among them, 50 people (0.05%) have Red cell distribution width increased.

Could Carvedilol cause Red cell distribution width increased?

Among these 50 people:

What is the gender of people who have Red cell distribution width increased when taking Carvedilol? *

female: 47.22 %
male: 52.78 %

What is the age of people who have Red cell distribution width increased when taking Carvedilol? *

What are other drugs people take besides Carvedilol? *

What are other side effects people have besides Red cell distribution width increased? *

Red Blood Cell Count Decreased: 32 people, 64.00%
Haematocrit Decreased: 31 people, 62.00%
Haemoglobin Decreased: 30 people, 60.00%
Lymphocyte Count Decreased: 27 people, 54.00%
Blood Glucose Increased: 26 people, 52.00%
Thrombocytopenia (decrease of platelets in blood): 19 people, 38.00%
Monocyte Count Increased: 17 people, 34.00%
Blood Urea Increased: 17 people, 34.00%
White Blood Cell Count Decreased: 13 people, 26.00%
Glomerular Filtration Rate Decreased: 12 people, 24.00%

What are the existing conditions these people have? *

Hereditary Neuropathic Amyloidosis (hereditary- diseases resulting from abnormal deposition of certain proteins (amyloid) in various bodily areas by problems with signals from the nerves): 9 people, 18.00%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 10.00%
Primary Myelofibrosis (primary disorder of the bone marrow): 5 people, 10.00%
Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 5 people, 10.00%
Pain: 5 people, 10.00%
Renal Cell Carcinoma (a kidney cancer): 4 people, 8.00%
Cardiac Failure: 4 people, 8.00%
Cardiac Failure Congestive: 3 people, 6.00%
High Blood Cholesterol: 3 people, 6.00%
Breast Cancer: 3 people, 6.00%

* Approximation only. Some reports may have incomplete information.

Do you take Carvedilol and have Red cell distribution width increased?

- Check whether Red cell distribution width increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Carvedilol:

Carvedilol (112,649 reports)

Browse all side effects of Carvedilol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Red cell distribution width increased:

Red cell distribution width increased (604 drugs)

Browse all the conditions that are associated with Red cell distribution width increased:

Red cell distribution width increased (656 conditions)

Related publications that referenced our studies

Barold, S. S., & Upton, S. , "Hyperkalemia Induced by the Sequential Administration of Metoprolol and Carvedilol", Case reports in cardiology, 2018 Jan .
Kim MS, Baek IH, "Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats", European Journal of Pharmaceutical Sciences, 2018 Jan .
Barold, S. S., & Upton, S. , "Hyperkalemia Induced by the Sequential Administration of Metoprolol and Carvedilol", Case reports in cardiology, 2018 Jan .
Kim MS, Baek IH, "Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats", European Journal of Pharmaceutical Sciences, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on carvedilol (the active ingredients of Carvedilol) and Carvedilol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.